
Sign up to save your podcasts
Or


Patients with hypertension at risk for cardiovascular events have done better with an ACE inhibitor-calcium channel blocker combination than with the ACE inhibitor plus hydrochlorothiazide. The ACCOMPLISH investigators have now reported on their analysis of progression-of-nephropathy outcomes in their trial. We interview the first author of the analysis, Dr. George Bakris of the University of Chicago’s Pritzker School of Medicine.
Interview-related links:
News-related links:
By NEJM Group4.5
5656 ratings
Patients with hypertension at risk for cardiovascular events have done better with an ACE inhibitor-calcium channel blocker combination than with the ACE inhibitor plus hydrochlorothiazide. The ACCOMPLISH investigators have now reported on their analysis of progression-of-nephropathy outcomes in their trial. We interview the first author of the analysis, Dr. George Bakris of the University of Chicago’s Pritzker School of Medicine.
Interview-related links:
News-related links:

7,599 Listeners

318 Listeners

2,059 Listeners

125 Listeners

496 Listeners

293 Listeners

885 Listeners

263 Listeners

3,340 Listeners

112,032 Listeners

90 Listeners

5 Listeners

92 Listeners

513 Listeners

2,548 Listeners

368 Listeners

15,832 Listeners

61 Listeners

31 Listeners

66 Listeners